The company and the Institute of Radiation and Radiation Medicine of the Academy of Military Medical Sciences jointly developed a new anticoagulant drug - recombinant neohirudin for injection (EH). Compared with heparin and hirudin, it has the characteristics of good stability, specificity, safety and low bleeding. It provides a new antithrombotic drug with high efficiency, low toxicity, high quality and low cost for the majority of thrombosis patients.In 2009, the drug was funded by the National Key New Drug Creation Science and Technology Major Special Subsidy. In 2016, the drug clinical trial approval (approval number: 2016L0108) was obtained, and the phase I clinical trial was completed in June 2018.
